Home > Seminars > Supramolecular Engineering of Peptide and Protein Therapeutics

Supramolecular Engineering of Peptide and Protein Therapeutics

Start:

1/26/2016 at 12:30PM

End:

1/26/2016 at 1:30PM

Location:

136 DeBartolo Hall

Host:

College of Engineering close button
headerbottom

Edward Maginn

Edward Maginn

VIEW FULL PROFILE Email: ed@nd.edu
Phone: 574-631-5687
Website: http://www.nd.edu/~ed/
Office: 182A Fitzpatrick Hall

Affiliations

Department of Chemical and Biomolecular Engineering Dorini Family Professor of Energy Studies and Department Chair
College of Engineering Dorini Family Professor of Energy Studies and Chair of the Department of Chemical and Biomolecular Engineering
The research in our group focuses on developing a fundamental understanding of the link between the physical properties of materials and their chemical constitution. Much of our work is devoted to applications related to energy and the environment. The main tool we use is molecular simulation. In ...
Click for more information about Edward
574-631-5687
Add to calendar:
iCal vCal

Through molecular engineering, it is possible to address complexities associated with the deficiencies and dynamics of diseases, such as ischemia and diabetes, in order to engineer improved therapies. The biological relevance of peptides, and the ability to precisely engineer supramolecular interactions through directional assembly and organized hydrogen bonding, enables the generation of platforms that can be utilized as functional therapeutic materials. These bio-inspired materials interface with biology and physiology in a mimetic and active way. Self-assembling peptides can be used to present potent bioactive signals at high density to mimic the function of angiogenic growth factors, or to prepare favorable niches for stem and progenitor cell therapeutics. Molecular interactions can additionally be leveraged to alter therapeutic dynamics and afford aspects of biologically relevant sensing in molecularly engineered protein therapies. Diabetes, and the complexities associated with glycemic control, present a significant engineering constraint in the design of therapies to recapitulate and replace the dynamics of native insulin signaling. Through covalent modification of insulin with molecular recognition motifs and aliphatic groups, the kinetics of insulin activity can be modulated by glucose-mediated dynamic covalent interactions, resulting in biomimetic insulin therapy. Alternatively, precise supramolecular host-guest interactions can be used to tune both the stability and activity of a broad suite of biopharmaceuticals, including insulin. In sum, these findings point to a new era of rationally engineered therapies rooted in predictable, biomimetic, tunable, and dynamic intermolecular and supramolecular interactions.

Seminar Speaker:

Matthew Webber

Matthew Webber

Massachusetts Institute of Technology

Dr. Matthew Webber received a BSc in Chemical Engineering from the University of Notre Dame, graduating with honors and receiving an award for excellence in undergraduate research. He then obtained both MS and PhD degrees in Biomedical Engineering from Northwestern University. His dissertation, performed in the laboratory of Prof. Samuel Stupp, focused on the use supramolecular peptide assemblies for cardiovascular disease therapeutics. While at Northwestern, he was supported by an NIH fellowship through the Regenerative Medicine Training Program, and his dissertation research was awarded the Acta Biomaterialia Student Award and the Northwestern BME Dudley Childress Award. He is presently an NIH NRSA postdoctoral fellow in the laboratories of Prof. Robert Langer and Prof. Daniel Anderson at MIT, working on the development of new molecular engineering approaches toward the treatment of diabetes. He co-chaired the inaugural Gordon Research Symposium on Biomaterials and Tissue Engineering in 2013, and organized a New Frontiers Symposium on Supramolecular Biomaterials for the 2016 World Biomaterials Congress.  His research passion is to contribute to bringing the field of Supramolecular Therapeutics into prominence. He has authored 38 peer-reviewed papers, is inventor on 5 pending or awarded patents, and has been committed to the education and training of many students and researchers through his teaching and mentorship. His personal interests include Notre Dame football, eating BBQ, and spending time with his wife and daughter.

« June 2019 »
June
SuMoTuWeThFrSa
1
2345678
9101112131415
16171819202122
23242526272829
30